Invitae (OTC:NVTA), backed by Softbank (OTCPK:SFTBY) and Cathie Wood's Ark Investment Management, filed for Chapter 11 bankruptcy protection, to address the genetic-testing company's more than $1B ...

– Using Invitae's Ciitizen patient-driven data platform, AstraZeneca and the Cholangiocarcinoma Foundation will access lived experience of patients with a rare cancer to drive further research – – ...

Spotlight Top Pick InVitae Corp (NYSE:NVTA) has seen its stock decline and one culprit was a recently published article “How a cancer test maker started by former Twitter, Google execs hopes to change ...

Just a few weeks after earning a permanent injunction barring the use of Invitae’s Personalized Cancer Monitoring tests, Natera is taking another of the diagnostic developer’s product portfolios off ...

– Blue Shield of California has over 3 million covered members in CA – SAN FRANCISCO, March 6, 2023 /PRNewswire/ -- Invitae (NVTA), a leading medical genetics company, today announced that its ...

Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously said that 'Volatility is far from synonymous with risk.' So it might be obvious ...

It's been a busy day for Invitae. The genetic testing provider inked a $200 million buyout and wrapped up a hefty investment from a group of backers marshaled by SoftBank. Just how hefty? $1.15 ...